Project VerioVue Enhancements - Arterial Study

Sponsor
LifeScan Scotland Ltd (Industry)
Overall Status
Completed
CT.gov ID
NCT06121856
Collaborator
(none)
116
1
2.6
44.1

Study Details

Study Description

Brief Summary

The aim of this performance evaluation is to compare the blood glucose results obtained using the VerioVue Blood Glucose Monitoring System (BGMS) with those obtained from a validated comparator method (iSTAT 1 Analyser) using arterial blood. The main question the study aims to answer is:

How accurate is the VerioVue BGMS when compared to a product that has already been confirmed as accurate (iSTAT 1 Analyser) when hospital staff test arterial blood on these two types of instrument? Participants will have a small amount of blood taken from an existing arterial line.

Condition or Disease Intervention/Treatment Phase
  • Device: VerioVue Enhancements BGMS

Detailed Description

Up to two UK NHS hospital sites will be used to collect a minimum of 100 evaluable samples from participants fitted with an arterial line that meet the acceptance criteria. Consent will be obtained from the participants prior to taking part in the study. If the participant meets the enrolment criteria then demographics and medical history information will be collected. A small volume of blood (max 150µl) will be collected from an existing arterial line. The blood will then be applied to six investigational OneTouch VerioVue meters (with expanded haematocrit range 20-65%) fitted with OneTouch Verio test strips and the blood glucose meter readings recorded. Three different lots of test strips will be used in rotation across the study. Within 5 minutes of the last meter test, trained staff will use blood from the same sample and perform a test on the iSTAT Analyser to obtain the blood glucose, haematocrit and oxygen levels of the sample. No treatment decisions will be made based on the blood glucose results obtained for this study. The study documentation will be reviewed by LifeScan monitors for completeness and accuracy and the results entered into a validated database. The data will be extracted and statistically analysed to determine the accuracy of the arterial blood glucose results obtained using the OneTouch VerioVue BGMS when compared to the arterial blood glucose results obtained on the iSTAT 1 Analyser.

Study Design

Study Type:
Observational
Actual Enrollment :
116 participants
Observational Model:
Case-Only
Time Perspective:
Cross-Sectional
Official Title:
VerioVue Enhancements Regulatory Clinical Evaluation - Professional Comparison to Validated Method: Arterial Study
Actual Study Start Date :
Feb 7, 2023
Actual Primary Completion Date :
Apr 28, 2023
Actual Study Completion Date :
Apr 28, 2023

Arms and Interventions

Arm Intervention/Treatment
In-patients cardiothoracic intensive care

In-patients in the cardiothoracic intensive care department that were at least 16 years old and were fitted with an arterial line. There was no requirement to have diabetes but the study aimed to recruit a minimum of 20% subjects with diabetes.

Device: VerioVue Enhancements BGMS
Blood glucose monitoring system

Outcome Measures

Primary Outcome Measures

  1. Performance evaluation: blood glucose monitoring system accuracy: BGMS vs reference instrument using arterial blood [Within 30 minutes of arterial blood sample draw.]

    Performance Evaluation to compare the VerioVue BGMS blood glucose results to results obtained using the iSTAT 1 Analyser, a validated comparator method when using arterial blood.

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Age - The potential Subject is at least 16 years old. Language - Subject reads and understands English. Informed Consent - The potential subject must read the Participant Information Sheet and sign the Informed Consent Form.

Subject agrees to provide relevant demographic, medical history, and prescription medication information.

The subject agrees to allow study staff access to medical records where necessary.

The Subject agrees to all aspects of the study process, including arterial blood draws performed by an HCP.

Exclusion Criteria:

Age - Subject is under 16 years old. Current Covid-19 positive test result.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Royal Infirmary of Edinburgh Edinburgh United Kingdom LE4 0ER

Sponsors and Collaborators

  • LifeScan Scotland Ltd

Investigators

  • Principal Investigator: Nicola Zammitt, MBChB, Edinburgh Centre for Endocrinology and Diabetes

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
LifeScan Scotland Ltd
ClinicalTrials.gov Identifier:
NCT06121856
Other Study ID Numbers:
  • FILE-PROT-005439
First Posted:
Nov 8, 2023
Last Update Posted:
Nov 8, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Nov 8, 2023